Today, we reported our Q2 #FinancialResults and provided corporate updates. We will host a conference call today at 8 am EDT. Learn more: https://bit.ly/4fOwCIn
Madrigal Pharmaceuticals
Pharmaceutical Manufacturing
Conshohocken, Pennsylvania 43,618 followers
Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
About us
Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com.
- Website
-
https://www.madrigalpharma.com/
External link for Madrigal Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Conshohocken, Pennsylvania
- Type
- Public Company
- Founded
- 2016
- Specialties
- Liver Disease, NASH, Metabolic Disease, and MASH
Locations
-
Primary
200 Barr-Harbor Dr
Suite 200
Conshohocken, Pennsylvania 19428, US
Employees at Madrigal Pharmaceuticals
Updates
-
Today, we announced the appointment of Shannon Kelley as General Counsel. Shannon has played an instrumental role guiding the company through a period of rapid growth and we look forward to her continued leadership. Learn more here: https://bit.ly/3SxUG8a
-
Madrigal Pharmaceuticals reposted this
“For launch, we took a data-first approach, ultimately knowing that understanding our customers was imperative to our launch strategy.” Hear Gavin Dawson, Senior Director, Data Strategy and Analytics at Madrigal Pharmaceuticals, explain why they implemented a fully-integrated data foundation years ahead of launch to align stakeholders and commercialize with speed and precision. #biopharma #lifesciences #VeevaOpenData
-
Madrigal Pharmaceuticals reposted this
Watch how a community engages with a realistic liver model at our recent community liver health education and screening event: https://lnkd.in/g9PeyEY2 Liam Swain (recently accepted into medical school) interacts closely wth a very curious group of attendees at our Global Fatty Liver Day event. Link to video: https://lnkd.in/g9PeyEY2 American Association for the Study of Liver Diseases (AASLD) EASL | The Home of Hepatology European Liver Patients' Association - ELPA LPI LIVER PATIENTS INTERNATIONAL Global Liver Institute, Canadian Association for the Study of the Liver, Prof. Shira Zelber Sagi, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, Rachael Sood RN, MSN, NP-C, CDCES, Arizona Liver Health, Naim Alkhouri, MD, FAASLD, Mazen Noureddin, MD, MHSc, Jörn M. Schattenberg, Zobair Younossi, Global NASH Council, Obesity Matters , Paul Brennan, Christopher Kopka, American Diabetes Association, Barcelona Institute for Global Health (ISGlobal), Jeffrey V. Lazarus, Dexcom, Michael Reiner, MBA, Elizabeth Pekas, PhD, Donna Cryer, Madrigal Pharmaceuticals, Chris Frates, Chris Dadas
-
We’ll be in Orlando, FL for the American Diabetes Association's 84th Scientific Sessions. Will you? Stop by our e-poster session on #NASH / #MASH between 12:30-1:30 p.m. EDT on Sunday, June 23. Swipe to learn more. #ADA2024
-
This Global #FattyLiverDay, we welcomed Kim and Bruce who shared their personal experiences living with #NASH / #MASH. It’s stories like these that keep us driven in our efforts toward fighting this disease. Learn about our progress in NASH: https://bit.ly/49gCAgl.
-
We are proud to sponsor Global Liver Institute's Global #FattyLiverDay, an awareness initiative that prioritizes the lives of those impacted by #NASH / #MASH. Help us increase education by joining the conversation.
This Global #FattyLiverDay hear from our Founder and CEO, Donna Cryer, as she shares what today can mean for patients with #FattyLiverDisease. Learn more: https://lnkd.in/gwNfFW3e #ActNowScreenToday #Liverhealth #FattyLiver #NASH #MASH
-
Advocates like Susan remind us why our research and innovative efforts play a critical role in the lives of people living with fatty liver disease. This Global #FattyLiverDay, please take the time to listen to Susan’s hope for the #NASH / #MASH community.
-
On Global #FattyLiverDay, our CEO Bill Sibold expresses his gratitude for the #NASH / #MASH community, reminding us the role we can all play in the fight against liver disease.
It’s been a tremendous year filled with so much progress and excitement for the #NASH / #MASH community. As we recognize Global #FattyLiverDay, I want to take a moment to thank and acknowledge this resilient community. Your experiences, stories and advice serve as inspiration for all of us at Madrigal Pharmaceuticals as we navigate and tackle the challenges of NASH together. We’ve made significant strides over the last few months and we're just getting started. Days like today serve as a reminder of our collective responsibility to raise awareness and educate those around us on the seriousness of NASH. Even the smallest efforts and changes can have a big impact on helping improve health outcomes for patients living with NASH. Together, we will continue pushing the boundaries in our fight against #LiverDisease!
-
Honoring Global Liver Institute’s Global #FattyLiverDay, we want to thank the #NASH / #MASH community for its continued efforts in helping those living with this disease. Our Madrigal team remains committed to those who share the same mission in raising awareness, promoting education and fostering support to help create healthier, happier lives.